The role of chemotherapy and new targeted agents in the management of primary prostate cancer

被引：3
作者：
Kumar, Sanjeev Srinivas [1 ]
Pacey, Simon [1 ]
机构：
[1] Addenbrookes Hosp, Dept Oncol, Box 193, Cambridge CB2 0QQ, England
来源：
JOURNAL OF CLINICAL UROLOGY | 2016年 / 9卷 / 02期
关键词：
Prostate; primary; cancer; neoadjuvant; adjuvant; hormone therapy; chemotherapy; targeted therapy; molecular; personalised therapy;
D O I：
10.1177/2051415816685211
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
While early treatment of primary prostate cancer is very effective, the incidence of primary prostate cancer continues to rise and therefore the detection of men with high-risk non-metastatic prostate cancer and their subsequent management is becoming increasingly important. There continues to be no molecularly-targeted or chemotherapeutic options with proven, statistically significant survival benefit in this setting. However, there are indications that further risk stratification using molecular features could potentially help distinguish indolent from aggressive prostate cancer, ultimately providing biological markers that could guide a more personalised approach to therapy selection.
引用
收藏
页码：30 / 37
页数：8
相关论文
共 76 条
  • [11] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
    Chi, KN
    Eisenhauer, E
    Fazli, L
    Jones, EC
    Goldenberg, SL
    Powers, J
    Tu, DS
    Gleave, ME
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) : 1287 - 1296
  • [12] Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer
    Clark, PE
    Peereboom, DM
    Dreicher, R
    Levin, HS
    Clark, SB
    Klein, EA
    [J]. UROLOGY, 2001, 57 (02) : 281 - 285
  • [13] Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
    Cooper, Colin S.
    Eeles, Rosalind
    Wedge, David C.
    Van Loo, Peter
    Gundem, Gunes
    Alexandrov, Ludmil B.
    Kremeyer, Barbara
    Butler, Adam
    Lynch, Andrew G.
    Camacho, Niedzica
    Massie, Charlie E.
    Kay, Jonathan
    Luxton, Hayley J.
    Edwards, Sandra
    Kote-Jarai, Zsofia
    Dennis, Nening
    Merson, Sue
    Leongamornlert, Daniel
    Zamora, Jorge
    Corbishley, Cathy
    Thomas, Sarah
    Nik-Zainal, Serena
    O'Meara, Sarah
    Matthews, Lucy
    Clark, Jeremy
    Hurst, Rachel
    Mithen, Richard
    Bristow, Robert G.
    Boutros, Paul C.
    Fraser, Michael
    Cooke, Susanna
    Raine, Keiran
    Jones, David
    Menzies, Andrew
    Stebbings, Lucy
    Hinton, Jon
    Teague, Jon
    McLaren, Stuart
    Mudie, Laura
    Hardy, Claire
    Anderson, Elizabeth
    Joseph, Olivia
    Goody, Victoria
    Robinson, Ben
    Maddison, Mark
    Gamble, Stephen
    Greenman, Christopher
    Berney, Dan
    Hazell, Steven
    Livni, Naomi
    [J]. NATURE GENETICS, 2015, 47 (04) : 367 - U118
  • [14] Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
    Cooperberg, Matthew R.
    Broering, Jeanette M.
    Carroll, Peter R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1117 - 1123
  • [15] Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Fondurulia, J
    Chen, MH
    Kaplan, I
    Beard, CJ
    Tomaszewski, JE
    Renshaw, AA
    Wein, A
    Coleman, CN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 168 - 172
  • [16] Efstathiou E, 2012, ASCO M, V30, P4556
  • [17] Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer
    Efstathiou, Eleni
    Troncoso, Patricia
    Wen, Sijin
    Do, Kim-Anh
    Pettaway, Curtis A.
    Pisters, Louis L.
    McDonnell, TimothyJ.
    Logothetis, ChristopherJ.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1224 - 1231
  • [18] The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
    Fair, WR
    Cookson, MS
    Stroumbakis, N
    Cohen, D
    Aprikian, AG
    Wang, Y
    Russo, P
    Soloway, SM
    Sogani, P
    Sheinfeld, J
    Herr, H
    Dalgabni, G
    Begg, CB
    Heston, WDW
    Reuter, VE
    [J]. UROLOGY, 1997, 49 (3A) : 46 - 55
  • [19] Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer
    Febbo, PG
    Thorner, A
    Rubin, MA
    Loda, M
    Kantoff, PW
    Oh, WK
    Golub, T
    George, D
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 152 - 158
  • [20] Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Febbo, PG
    Richie, JP
    George, DJ
    Loda, M
    Manola, J
    Shankar, S
    Barnes, AS
    Tempany, C
    Catalona, W
    Kantoff, PW
    Oh, WK
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5233 - 5240
12345678